+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Secondary Myelofibrosis Therapeutics Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 200 Pages
  • September 2023
  • Region: Global
  • Expert Market Research
  • ID: 5895124
The secondary myelofibrosis therapeutics market size was valued at USD 2 billion in 2023, driven by increasing awareness, improved diagnostic techniques, and the development of targeted therapies has led to market growth across the globe. The market size is anticipated to grow at a CAGR of 7.2% during the forecast period of 2024-2032 to achieve a value of USD 3.8 billion by 2032.

Secondary Myelofibrosis Therapeutics: Introduction

Secondary myelofibrosis, also known as post-polycythemia vera/post-essential thrombocythemia myelofibrosis, is a rare hematological disorder characterized by the development of fibrosis in the bone marrow. It is considered a complication of other myeloproliferative neoplasms (MPNs), such as polycythemia vera (PV) or essential thrombocythemia (ET). In secondary myelofibrosis, the abnormal proliferation of blood cells in PV or ET leads to the accumulation of scar tissue (fibrosis) in the bone marrow, which impairs its normal function.

The development of secondary myelofibrosis is believed to be a result of genetic mutations and dysregulated signaling pathways within the bone marrow cells. Over time, the fibrotic changes can lead to the replacement of healthy bone marrow cells with fibrous tissue, causing a disruption in the production of blood cells and leading to a variety of symptoms.

Key Trends in the Secondary Myelofibrosis Therapeutics Market

Key trends in the secondary myelofibrosis therapeutics market reflect advancements in research, increasing understanding of disease biology, and the development of targeted therapies. These trends are shaping the landscape of treatment options and have the potential to improve outcomes for patients with secondary myelofibrosis. Some key trends in the secondary myelofibrosis therapeutics market include:

  • Targeted Therapies: The development of targeted therapies specifically designed to address the underlying molecular abnormalities in secondary myelofibrosis is a significant trend. These therapies aim to inhibit dysregulated signaling pathways, such as the JAK-STAT pathway, which play a crucial role in the development and progression of myelofibrosis.
  • Combination Therapies: Combination therapies involving different targeted agents or a combination of targeted therapies with conventional treatments are being explored. This approach aims to enhance treatment efficacy and potentially overcome resistance to single-agent therapies.
  • Improved Diagnostic Techniques: Advances in diagnostic techniques, such as next-generation sequencing and molecular profiling, are enabling better characterization of the genetic mutations and molecular abnormalities associated with secondary myelofibrosis. These techniques help identify specific biomarkers that can guide treatment decisions and predict response to therapy.
  • Supportive Care Measures: There is an increasing recognition of the importance of supportive care measures in the management of secondary myelofibrosis. Supportive care interventions focus on addressing symptoms, improving quality of life, and managing complications associated with the disease.
  • Patient-Centric Approaches: Patient-centric approaches, including shared decision-making and patient-reported outcomes, are gaining importance in the management of secondary myelofibrosis. The involvement of patients in treatment decisions and assessing treatment outcomes helps tailor therapy to individual needs and preferences.

Secondary Myelofibrosis Therapeutics Market Segmentations

The market can be categorized into therapy type, drug class, and region.

Market Breakup by Therapy Type

  • Targeted Therapy
  • Chemotherapy
  • Radiation Therapy

Market Breakup by Drug Class

  • Ruxolitnab
  • Fedratinib
  • Pomalidomide

Market Breakup by Region -7MM

  • United States
  • EU-4 and the United Kingdom
  • Japan

Secondary Myelofibrosis Therapeutics Market Overview

The market for secondary myelofibrosis therapeutics is a segment within the broader haematological disorders and oncology markets. It focuses on the development, manufacturing, and commercialization of therapies for secondary myelofibrosis, which is a rare and chronic haematological disorder characterized by the development of fibrosis in the bone marrow as a complication of other myeloproliferative neoplasms (MPNs), such as polycythemia vera (PV) or essential thrombocythemia (ET).

The secondary myelofibrosis therapeutics market is relatively small compared to other segments within the oncology field due to the rarity of the condition. However, the market is expected to grow steadily due to increasing awareness, improved diagnostic techniques, and the development of targeted therapies. The introduction of novel therapies and ongoing research in the field offer opportunities for market expansion.

The market for secondary myelofibrosis therapeutics is primarily driven by developed regions such as North America and Europe, where healthcare infrastructure, research and development activities, and access to advanced therapies are well-established. However, there is an increasing focus on improving healthcare infrastructure and access to innovative treatments in emerging markets, particularly in the Asia Pacific region.

Key Players in the Secondary Myelofibrosis Therapeutics Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

The major companies in secondary myelofibrosis therapeutics market are as follows:

  • Competition Deep Dive
  • Incyte Corporation
  • Bristol-Myers Squibb Company
  • Amneal Pharmaceuticals, Inc.
  • AbbVie Inc.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Actuate Therapeutics Inc.
  • Imago Biosciences
  • Galecto, Inc
The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Secondary Myelofibrosis Therapeutics Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Global Secondary Myelofibrosis Therapeutics Epidemiology Analysis
5.1 Epidemiology Overview (2017-2032)
5.2 North America Global Secondary Myelofibrosis Therapeutics Epidemiology (2017-2032)
5.3 Europe Global Secondary Myelofibrosis Therapeutics Epidemiology (2017-2032)
5.4 Asia-Pacific Global Secondary Myelofibrosis Therapeutics Epidemiology (2017-2032)
5.5 Latin America Global Secondary Myelofibrosis Therapeutics Epidemiology (2017-2032)
5.6 Middle East & Africa Global Secondary Myelofibrosis Therapeutics Epidemiology (2017-2032)
6 Global Secondary Myelofibrosis Therapeutics Market Overview
6.1 Global Secondary Myelofibrosis Therapeutics Market Historical Value (2017-2023)
6.2 Global Secondary Myelofibrosis Therapeutics Market Forecast Value (2024-2032)
7 Global Secondary Myelofibrosis Therapeutics Market Landscape
7.1 Global Secondary Myelofibrosis Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Secondary Myelofibrosis Therapeutics: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Applications
8 Global Secondary Myelofibrosis Therapeutics Market Dynamics
8.1 Market Drivers and Constraints
8.2 SWOT Analysis
8.3 Porter’s Five Forces Model
8.4 Key Demand Indicators
8.5 Key Price Indicators
8.6 Industry Events, Initiatives, and Trends
8.7 Value Chain Analysis
9 Global Secondary Myelofibrosis Therapeutics Market Segmentation
9.1 Global Secondary Myelofibrosis Therapeutics Market by Type
9.1.1 Market Overview
9.1.2 Targeted Therapy
9.1.3 Chemotherapy
9.1.4 Radiation Therapy
9.2 Global Secondary Myelofibrosis Therapeutics Market by Diagnosis
9.2.1 Market Overview
9.2.2 Physical Tests
9.2.3 Imaging Tests
9.2.4 Blood Tests
9.3 Global Secondary Myelofibrosis Therapeutics Market by Drug Class
9.3.1 Market Overview
9.3.2 Ruxolitnab
9.3.3 Fedratinib
9.3.4 Pomalidomide
9.4 Global Secondary Myelofibrosis Therapeutics Market by Region
9.4.1 Market Overview
9.4.2 North America
9.4.3 Europe
9.4.4 Asia Pacific
9.4.5 Latin America
9.4.6 Middle East and Africa
10 North America Secondary Myelofibrosis Therapeutics Market
10.1 Market Share by Country
10.2 United States of America
10.3 Canada
11 Europe Secondary Myelofibrosis Therapeutics Market
11.1 Market Share by Country
11.2 United Kingdom
11.3 Germany
11.4 France
11.5 Italy
11.6 Others
12 Asia Pacific Secondary Myelofibrosis Therapeutics Market
12.1 Market Share by Country
12.2 China
12.3 Japan
12.4 India
12.5 ASEAN
12.6 Australia
12.7 Others
13 Latin America Secondary Myelofibrosis Therapeutics Market
13.1 Market Share by Country
13.2 Brazil
13.3 Argentina
13.4 Mexico
13.5 Others
14 Middle East and Africa Secondary Myelofibrosis Therapeutics Market
14.1 Market Share by Country
14.2 Saudi Arabia
14.3 United Arab Emirates
14.4 Nigeria
14.5 South Africa
14.6 Others
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 INDIA CDSCO
15.1.4 JAPAN PMDA
15.1.5 Others
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Funding and Investment Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Competition Deep Dive
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisitions
20.1.5 Certifications
20.2 Incyte Corporation
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisitions
20.2.5 Certifications
20.3 Bristol-Myers Squibb Company
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisitions
20.3.5 Certifications
20.4 Amneal Pharmaceuticals, Inc.
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisitions
20.4.5 Certifications
20.5 AbbVie Inc.
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisitions
20.5.5 Certifications
20.6 GlaxoSmithKline plc
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisitions
20.6.5 Certifications
20.7 Pfizer Inc.
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisitions
20.7.5 Certifications
20.7.6 Shenzhen
20.8 Actuate Therapeutics Inc.
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisitions
20.8.5 Certifications
20.9 Imago Biosciences
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisitions
20.9.5 Certifications
20.10 Galecto, Inc
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisitions
20.10.5 Certifications
21 Key Opinion Leaders (KOL) Insights (Additional Insight)
22 Company Competitiveness Analysis (Additional Insight)
22.1 Very Small Companies
22.2 Small Companies
22.3 Mid-Sized Companies
22.4 Large Companies
22.5 Very Large Companies
23 Payment Methods (Additional Insight)
23.1 Government Funded
23.2 Private Insurance
23.3 Out-of-Pocket

Companies Mentioned

  • Competition Deep Dive Incyte Corporation
  • Bristol-Myers Squibb Company
  • Amneal Pharmaceuticals Inc.
  • AbbVie Inc.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Actuate Therapeutics Inc.
  • Imago Biosciences
  • Galecto Inc

Methodology

Loading
LOADING...